BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
AAPG upcoming catalysts
Ascentage Pharma Group Inc.: 2 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 4 readout(s) and 0 FDA event(s). Subscribe to AAPG (.ics).
Drugs: APG2575, lisaftoclax, BTK inhibitor, Toripalimab, pembrolizumab
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Ascentage Pharma Group Inc. AAPG | NCT05147467 Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | recruiting | 75 |
| 2026-12-31 est. | P3 | Ascentage Pharma Group Inc. AAPG | NCT06104566 Global Trial in APG2575 for Patients With CLL/SLL | CLL/SLL | recruiting | 400 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No FDA decision events in this window. | |||||
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-05-31 est. | P2 | Ascentage Pharma Group Inc. AAPG | NCT04496349 A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL | T-Prolymphocytic Leukemia; Non-Hodgkins Lymphoma | recruiting | 78 |
| 2026-04 est. | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT06182969 A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. | SLE | recruiting | 40 |
| 2026-04 est. | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT04785196 APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | Liposarcoma; Advanced Solid Tumor | recruiting | 95 |
| 2025-12-30 est. | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT03611868 A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | Unresectable or Metastatic Melanoma or Advanced Solid Tumors; Melanoma; Uveal Melanoma; P53 Mutation | active not recruiting | 230 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.